These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28500685)

  • 1. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid.
    Bieber K; Ernst AL; Tukaj S; Holtsche MM; Schmidt E; Zillikens D; Ludwig RJ; Kasperkiewicz M
    Exp Dermatol; 2017 Dec; 26(12):1248-1252. PubMed ID: 28500685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid.
    Tedeschi A; Marzano AV; Lorini M; Balice Y; Cugno M
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):813-7. PubMed ID: 24650303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
    de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
    Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble CD200 level was higher in patients with bullous pemphigoid during the active phase of the disease than for healthy individuals.
    Akman-Karakaş A; Yalcin AD; Koç S; Gumuslu S; Ergun E; Genc GE; Ongut G; Uzun S; Alpsoy E
    Clin Lab; 2014; 60(7):1237-40. PubMed ID: 25134396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tryptase and myeloperoxidase levels in blister fluids of patients with bullous pemphigoid: correlations with cytokines, adhesion molecules and anti-basement membrane zone antibodies.
    D'Auria L; Pietravalle M; Cordiali-Fei P; Ameglio F
    Exp Dermatol; 2000 Apr; 9(2):131-7. PubMed ID: 10772387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome.
    Giusti D; Gatouillat G; Le Jan S; Plée J; Bernard P; Antonicelli F; Pham BN
    Sci Rep; 2017 Jul; 7(1):4833. PubMed ID: 28684769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180.
    Perriard J; Jaunin F; Favre B; Büdinger L; Hertl M; Saurat JH; Borradori L
    J Invest Dermatol; 1999 Feb; 112(2):141-7. PubMed ID: 9989787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers related to bullous pemphigoid activity and outcome.
    Giusti D; Le Jan S; Gatouillat G; Bernard P; Pham BN; Antonicelli F
    Exp Dermatol; 2017 Dec; 26(12):1240-1247. PubMed ID: 29105148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome.
    Plée J; Le Jan S; Giustiniani J; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Antonicelli F; Bernard P
    Sci Rep; 2015 Dec; 5():18001. PubMed ID: 26656739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities.
    Sun CC; Wu J; Wong TT; Wang LF; Chuan MT
    Br J Dermatol; 2000 Dec; 143(6):1235-40. PubMed ID: 11122027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
    Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
    Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay.
    Giusti D; Bini E; Terryn C; Didier K; Le Jan S; Gatouillat G; Durlach A; Nesmond S; Muller C; Bernard P; Antonicelli F; Pham BN
    Front Immunol; 2019; 10():701. PubMed ID: 31019514
    [No Abstract]   [Full Text] [Related]  

  • 16. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
    Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
    J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation.
    Engineer L; Bhol K; Kumari S; Razzaque Ahmed A
    Cytokine; 2001 Jan; 13(1):32-38. PubMed ID: 11145840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
    Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
    Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes/Macrophages and Mast Cells From Patients With Bullous Pemphigoid.
    Nesmond S; Muller C; Le Naour R; Viguier M; Bernard P; Antonicelli F; Le Jan S
    Front Immunol; 2019; 10():2107. PubMed ID: 31572359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.